Trials / Conditions / Salivary Gland Carcinoma

Salivary Gland Carcinoma

11 registered clinical trials studyying Salivary Gland Carcinoma — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Withdrawn	9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma NCT04832438	Actuate Therapeutics Inc.	Phase 2
Recruiting	Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematolog NCT07118176	Jonsson Comprehensive Cancer Center	Phase 1
Recruiting	Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing NCT06145308	Peking Union Medical College	Phase 2
Active Not Recruiting	Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT NCT05075980	Mayo Clinic	Phase 2
Recruiting	Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gl NCT03942653	Manish Patel	Phase 2
Completed	Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients With Salivary Gland Canc NCT03749460	University of Washington	Phase 1 / Phase 2
Completed	Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079	Klus Pharma Inc.	Phase 1 / Phase 2
Completed	Nivolumab in Recurrent or Metastatic Salivary Gland Carcinoma of the Head and Neck NCT03132038	UNICANCER	Phase 2
Unknown	Cell-free Tumor DNA in Head and Neck Cancer Patients NCT03942380	Christian von Buchwald	N/A
Active Not Recruiting	Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) NCT02628067	Merck Sharp & Dohme LLC	Phase 2
Completed	Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma NCT02393820	UNICANCER	Phase 2